3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
sargramostim
2
tislelizumab
1
spartalizumab
1
milademetan
1
devimistat
1
dehydroftorafur
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fluorouracil
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
bemarituzumab
×
Gynecologic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled